MSLE and MSCL Related Headlines
Go Back- Satellos Announces Upcoming Oral and Poster Presentations at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference
- Satellos to Host Virtual KOL Event on SAT-3247 in Duchenne Muscular Dystrophy
- Satellos to Participate in Upcoming Investor Conferences
- Satellos begins phase 2 trial of SAT-3247 for duchenne muscular dystrophy
- Satellos Announces First Participant Dosed in Phase 2 Pediatric Study of SAT-3247 for Duchenne Muscular Dystrophy
- Satellos to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit 2026
- Satellos raises $57.2 million in public offering across Canada and US
- Satellos Closes US$57.2 Million Public Offering in Canada and the United States, Including Exercise of Underwriters’ Option to Purchase Additional Shares
- Satellos prices $50 million public offering in Canada and US
- Satellos Announces Pricing of US$50 Million Public Offering in Canada and the United States
MSLE and MSCL Related Press Releases
Go Back- Satellos Announces Upcoming Oral and Poster Presentations at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference
- Satellos to Host Virtual KOL Event on SAT-3247 in Duchenne Muscular Dystrophy
- Satellos to Participate in Upcoming Investor Conferences
- Satellos Announces First Participant Dosed in Phase 2 Pediatric Study of SAT-3247 for Duchenne Muscular Dystrophy
- Satellos to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit 2026
- Satellos Closes US$57.2 Million Public Offering in Canada and the United States, Including Exercise of Underwriters’ Option to Purchase Additional Shares
- Satellos Announces Pricing of US$50 Million Public Offering in Canada and the United States
